Science and Technology Production
Revista Medicina - ALOE VERA, A NATURAL GROWTH INHIBITOR OF C. DIFFICILE
Congress
Authorship:
PALMA SABINA ; Español LA ; Hernández Del Pino RE ; Barbero AM ; Morro LS ; Machain M ; PASQUINELLI, VIRGINIADate:
2021Publishing House and Editing Place:
Fundación Revista Medicina (Buenos Aires)ISSN:
1669-9106Summary *
Aloe Vera (AV) gel exhibits antimicrobial and anti-inflammatory properties, making it an alternative therapy for intestinal disbiosis. The inner leaf gel contain active compounds with prebiotic activity on beneficial microbiota, while others compounds inhibit the growth of pathogenic bacteria. Clostridioides difficile (C. difficile), is a Gram-positive bacillus, an- aerobic, spore-forming, that constitutes the major cause of hospital-acquired diarrhea, often in association with previous antibiotic use. C. difficile infection (CDI) treatment is based on oral administration of metronidazole and vancomycin. The emergence and spread of C. difficile isolates resistant to multiple antibiotics, especially the hypervirulent ribotype 027 strains, are becoming an increasing problem for CDI treatment.We evaluate the AV effect on C. difficile growth, and its impact in combination with metronidazole and vancomycin. The antibacterial activity of AV was determined by broth microdilution assays using the hypervirulent C. difficile (027/BI/NAP1) strain. The bacteria were cultured in anaerobiosis for 48h, seeded in triplicates in 96 microwell plates in the presence of AV ± antibiotics. After 48h, C. difficile growth was determined in a microplate reader at 600nm. Two varieties of AV were used, Aloe barbadensis Miller and Aloe saporina, in final concentrations of 1, 5, 10, 20, 25 and 30%. The minimal inhibitory concentration (MIC) for metronidazole and vancomycin was calculated and the AV gel was used in combination with 0.25, 0.5, 1 and 2μg/ml of each antibiotic. The results indicated that AV gel inhibits C. difficile growth (p<0.01) and significantly reduces the MIC of metronidazole and vancomycin (p<0.05). This first evidence positions AV as a potential promising combination therapy against C. difficile, reducing the concentration of antibiotics treatment and the detrimental consequences on the beneficial microbiota. More studies are underway to strengthen this hypothesis. Information provided by the agent in SIGEVAKey Words
ALOE VERACLOSTRIDIOIDES DIFFICILEMICROBIOLOGÍA